Clinical trials: Hepatitis; Epidemic
Acute-on-chronic Hepatitis B Liver Failure
Characteristics and Risk Factors for Invasive Fungal Infection With Acute-on-chronic Hepatitis B Liver Failure
This is a single-center retrospective study. The clinical data of patients with Acute-on-chronic Hepatitis B liver failure who were hospitalized in the Department of Hepatology, Qilu Hospital of Shandong University from January…
- Trial name
- NCT06190002
- Volunteers
- 500 people
- Sponsor
- Qilu Hospital of Shandong University
Corona Virus Infection, Hepatitis
Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?
Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an…
- Trial name
- NCT04757272
- Where
- Egypt
- Volunteers
- 2,106 people
- Sponsor
- Zagazig University
Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B
The objective of this study was to evaluate the efficacy and safety of TVAX-008 Injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial in NAs-treated subjects with chronic…
- Trial name
- NCT07190742
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Hepatitis, Hepatitis C
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral…
- Trial name
- FITNESS (NCT00987337)
- Testing
- Filibuvir
- Where
- 77 sites in United States, Belgium and 7 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir
The purpose of the study is to 1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after…
- Trial name
- GENUPI (NCT01577069)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Association HGE CHU Bordeaux Sud
Hepatitis C
Study on the Prevalence of Hepatitis C In a psychiatRic Population
Viral hepatitis, especially hepatitis C, is a major public health issue. Nowadays, very few studies in France have evaluated the prevalence of hepatitis C in a psychiatric environment.
- Trial name
- SaPHIR (NCT04600479)
- Testing
- Evaluation of the prevalence of HCV, HBV and HIV viral infections
- Where
- 3 sites in France
- Volunteers
- 796 people
- Sponsor
- Nantes University Hospital
Chronic Hepatitis B
Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B
The aim of this study is to investigate the off-treatment sustained virological and biochemical response in chronic hepatitis B patients following the guideline by the Asian Pacific Association for the Study of the Liver (APASL)…
- Trial name
- NCT01533051
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
HBV Infection
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of…
- Trial name
- NCT07179653
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Alcoholic Hepatitis
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Inflammatory responses in response to alcohol have been identified as contributing to the development of alcoholic hepatitis. The inflammatory response including that to LippoPolySaccharide is known to lead to progression of…
- Trial name
- NCT04088370
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Hepatitis B Vaccines
Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China
Background Hepatitis B virus (HBV) co-infection in individuals with hepatitis C virus (HCV) can enhance the severity of hepatitis and the risks of liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT02898922
- Testing
- hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shandong Province Centers for Disease Control and Prevention
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Opioid Use Disorder, Infectious Disease
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of…
- Conditions
- Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use
- Trial name
- ACTION (NCT05286879)
- Testing
- Patient Navigator, Mobile Health Unit
- Where
- 3 sites in United States
- Volunteers
- 601 people
- Sponsor
- Yale University
Chronic HCV Infection, Nonalcoholic Steatohepatitis
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
In the presented project, the role of heme oxygenase 1 and 2 in the procesess associated with fibroproduction in the chronic HCV infection will be studied.
- Trial name
- NCT00842205
- Testing
- pegylated interferon, Ribavarin
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Charles University, Czech Republic
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso
This will be a study of the safety of MSP 3 LSP candidate malaria vaccine in children aged 1-2 years in Burkina Faso. Three imminizations at 28 day intervals will be administratered subcuteneously on the shoulder region.
- Trial name
- MSP3LSP (NCT00452088)
- Testing
- MSP 3 Long Synthetic Peptide, Hepatitis B vaccine, Hepatitis B control vaccince
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- African Malaria Network Trust
Hepatitis C Virus Infection
Screening, Treatment, and Eradication of Hep C
The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients/subjects through different methods of communication - text message, email, social media, radio, newspaper ads, and…
- Trial name
- NCT05071261
- Testing
- Hepatitis C Virus Screening
- Volunteers
- 112,136 people, healthy volunteers welcome
- Sponsor
- Liver Institute PLLC
Hepatitis C, Chronic
HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels
The main objective of this study is to assess the interest (linkage to care) of the Cepheid GeneXpert HCV VL Fingerstick test in Brussels among drug users or former users in contact with the Réseau Hépatite C Bruxelles…
- Trial name
- NCT04610762
- Testing
- GeneXpert HCV VL Fingerstick test
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Chronic Hepatitis B
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess efficacy and safety of Ypeginterferon alfa-2b, once a week, in 3 dose-groups: 90mcg, 135mcg and 180mcg, respectively…
- Trial name
- NCT01143662
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 39 sites in China
- Volunteers
- 205 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatitis C, Infectious Disease
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
Hepatitis C infection is a major cause of chronic liver disease and death with approximately 3% of the world's population is infected with hepatitis C virus (HCV).
- Trial name
- NCT03524794
- Where
- United Kingdom
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.